Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012.

Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna DL, Lenz HJ.

Oncotarget. 2016 Aug 16;7(33):53668-53678. doi: 10.18632/oncotarget.10696.

2.

Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.

Bohanes P, Rankin CJ, Blanke CD, Winder T, Ulrich CM, Smalley SR, Rich TA, Martensen JA, Benson AB 3rd, Mayer RJ, Cripps CM, Danenberg K, Makar KW, Zhang W, Benedetti JK, Lenz HJ.

Clin Cancer Res. 2015 Apr 1;21(7):1583-90. doi: 10.1158/1078-0432.CCR-14-0857. Epub 2015 Jan 14.

3.

Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.

Bohanes P, Yang D, Loupakis F, LaBonte MJ, Gerger A, Ning Y, Lenz C, Lenz F, Wakatsuki T, Zhang W, Benhaim L, El-Khoueiry A, El-Khoueiry R, Lenz HJ.

Pharmacogenomics J. 2015 Jun;15(3):226-34. doi: 10.1038/tpj.2014.66. Epub 2014 Dec 9.

PMID:
25487679
4.

Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.

Benhaim L, Zhang W, Wakatsuki T, Yang D, Gerger A, Bohanes P, Paez D, Loupakis F, LaBonte MJ, Ning Y, El-Khoueiry R, Ladner R, Wilson P, Zhang H, Giamas G, Stebbing J, Lenz HJ.

Pharmacogenomics J. 2015 Jun;15(3):235-40. doi: 10.1038/tpj.2014.58. Epub 2014 Oct 7.

PMID:
25287073
5.

Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients.

Loupakis F, Antoniotti C, Cremolini C, Zhang W, Yang D, Wakatsuki T, Bohanes P, Schirripa M, Salvatore L, Masi G, Ricci V, Graziano F, Ruzzo A, Benhaim L, Marmorino F, Ning Y, El-Khoueiry R, Falcone A, Lenz HJ.

Pharmacogenomics J. 2014 Aug;14(4):322-7. doi: 10.1038/tpj.2014.1. Epub 2014 Feb 11.

PMID:
24513691
6.

Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States.

Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, Loupakis F, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ.

Mol Cancer Ther. 2013 Oct;12(10):2261-72. doi: 10.1158/1535-7163.MCT-12-1134. Epub 2013 Aug 5.

7.

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.

Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ.

PLoS One. 2013 Jul 4;8(7):e66774. doi: 10.1371/journal.pone.0066774. Print 2013.

8.

Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.

Benhaim L, Gerger A, Bohanes P, Paez D, Wakatsuki T, Yang D, Labonte MJ, Ning Y, El-Khoueiry R, Loupakis F, Zhang W, Laurent-Puig P, Lenz HJ.

Pharmacogenomics J. 2014 Apr;14(2):135-41. doi: 10.1038/tpj.2013.21. Epub 2013 Jun 11.

PMID:
23752739
9.

Reply to J. Zhang et al.

Bohanes P, Yang D, Lenz HJ.

J Clin Oncol. 2013 Feb 20;31(6):816-7. No abstract available.

PMID:
23544202
10.

Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen.

Winder T, Giamas G, Wilson PM, Zhang W, Yang D, Bohanes P, Ning Y, Gerger A, Stebbing J, Lenz HJ.

Pharmacogenomics J. 2014 Feb;14(1):28-34. doi: 10.1038/tpj.2013.8. Epub 2013 Mar 5.

PMID:
23459444
11.

Influence of sex on the survival of patients with esophageal cancer.

Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, Gerger A, Benhaim L, Paez D, Wakatsuki T, Loupakis F, El-Khoueiry R, Zhang W, Lenz HJ.

J Clin Oncol. 2012 Jun 20;30(18):2265-72. doi: 10.1200/JCO.2011.38.8751. Epub 2012 May 14.

12.

An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence.

Winder T, Wilson PM, Yang D, Zhang W, Ning Y, Power DG, Bohanes P, Gerger A, Tang LH, Shah M, Lenz HJ.

Pharmacogenomics J. 2013 Aug;13(4):342-8. doi: 10.1038/tpj.2012.11. Epub 2012 Apr 10.

PMID:
22491017
13.

The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.

Ning Y, Labonte MJ, Zhang W, Bohanes PO, Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli Venkata KC, Louie SG, Petasis NA, Ladner RD, Lenz HJ.

Mol Cancer Ther. 2012 Jun;11(6):1353-64. doi: 10.1158/1535-7163.MCT-11-0915. Epub 2012 Mar 5.

14.

"HER majesty's a pretty nice girl but she changes from day to day".

Bohanes P, Loupakis F, Labonte MJ, Wakatsuki T, Lenz HJ.

J Clin Oncol. 2012 Feb 1;30(4):465-6; author reply 466-7. doi: 10.1200/JCO.2011.39.4098. Epub 2011 Dec 27. No abstract available.

PMID:
22203763
15.

Cancer dormancy: a model of early dissemination and late cancer recurrence.

Páez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ.

Clin Cancer Res. 2012 Feb 1;18(3):645-53. doi: 10.1158/1078-0432.CCR-11-2186. Epub 2011 Dec 9. Review.

16.

S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma.

Leichman LP, Goldman BH, Bohanes PO, Lenz HJ, Thomas CR, Billingsley KG, Corless CL, Iqbal S, Gold PJ, Benedetti JK, Danenberg KD, Blanke CD.

J Clin Oncol. 2011 Dec 1;29(34):4555-60. doi: 10.1200/JCO.2011.36.7490. Epub 2011 Oct 24.

17.

The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.

Labonte MJ, Wilson PM, Yang D, Zhang W, Ladner RD, Ning Y, Gerger A, Bohanes PO, Benhaim L, El-Khoueiry R, El-Khoueiry A, Lenz HJ.

Ann Oncol. 2012 Jun;23(6):1455-64. doi: 10.1093/annonc/mdr445. Epub 2011 Oct 11.

18.

Common cancer stem cell gene variants predict colon cancer recurrence.

Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ.

Clin Cancer Res. 2011 Nov 1;17(21):6934-43. doi: 10.1158/1078-0432.CCR-11-1180. Epub 2011 Sep 14.

19.

Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer.

Bohanes P, Courvoisier DS, Perneger TV, Morel P, Huber O, Roth AD.

Swiss Med Wkly. 2011 Aug 26;141:w13249. doi: 10.4414/smw.2011.13249.

20.

A review of excision repair cross-complementation group 1 in colorectal cancer.

Bohanes P, Labonte MJ, Lenz HJ.

Clin Colorectal Cancer. 2011 Sep;10(3):157-64. doi: 10.1016/j.clcc.2011.03.024. Epub 2011 Apr 28. Review.

PMID:
21855036
21.

Predictive molecular classifiers in colorectal cancer.

Bohanes P, LaBonte MJ, Winder T, Lenz HJ.

Semin Oncol. 2011 Aug;38(4):576-87. doi: 10.1053/j.seminoncol.2011.05.012. Review.

PMID:
21810517
22.

Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ.

Clin Cancer Res. 2011 Sep 1;17(17):5783-92. doi: 10.1158/1078-0432.CCR-11-1115. Epub 2011 Jul 26.

23.

GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients.

Winder T, Bohanes P, Zhang W, Yang D, Power DG, Ning Y, Gerger A, Wilson PM, Tang LH, Shah M, Lee AS, Lenz HJ.

Ann Oncol. 2011 Nov;22(11):2431-9. doi: 10.1093/annonc/mdq771. Epub 2011 Mar 7.

24.

Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma.

Winder T, Ning Y, Yang D, Zhang W, Power DG, Bohanes P, Gerger A, Wilson PM, Lurje G, Tang LH, Shah M, Lenz HJ.

Int J Cancer. 2011 Sep 1;129(5):1096-104. doi: 10.1002/ijc.25787. Epub 2011 Feb 11.

25.

Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).

Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A, Ning Y, Bohanes P, Gerger A, Winder T, Hollywood E, Danenberg KD, Saltz L, Lenz HJ.

Anticancer Res. 2010 Oct;30(10):4209-17.

PMID:
21036743
26.

Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.

Winder T, Zhang W, Yang D, Ning Y, Bohanes P, Gerger A, Wilson PM, Pohl A, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ.

Clin Cancer Res. 2010 Nov 15;16(22):5591-602. doi: 10.1158/1078-0432.CCR-10-2092. Epub 2010 Oct 8.

27.

[Gastric neoplasm, multidisciplinary management].

Bohanes Pi, Roth AD, Huber O, Aapro MS, Plan PA.

Rev Med Suisse. 2009 Aug 5;5(212):1569-75. Review. French. No abstract available.

PMID:
19728453
28.

Superior vena cava syndrome.

Landis BN, Bohanes P, Kohler R.

CMAJ. 2009 Feb 3;180(3):355. doi: 10.1503/cmaj.080754. No abstract available.

Supplemental Content

Loading ...
Support Center